Semaglutide is the first GLP-1 receptor agonist approved for clinical use. Understanding how it works requires understanding the two incretins it activates simultaneously.
Semaglutide is a once-weekly subcutaneous peptide injection. It works by selectively activating the GLP-1 (glucagon-like peptide-1) receptor — it is a single-receptor agonist, not a dual or triple agonist (tirzepatide is the dual GIP/GLP-1 agonist; semaglutide does not activate GIP). GLP-1 receptor activation produces appetite suppression via central nervous system signaling at hypothalamic appetite centers, delayed gastric emptying, glucose-dependent insulin secretion, and glucagon suppression. Onset of GI effects is typically within 1-2 weeks; peak effect on weight is observed at 60-68 weeks at the maintenance 2.4 mg dose. The albumin-binding side chain modification extends the half-life to approximately 7 days, enabling weekly dosing.
NexLife is structured around clinical best practices for semaglutide. The same flat-rate pricing applies across the entire titration schedule ($145/mo on the 12-month plan from 0.25 mg through 2.4 mg), labs are included, MD/DO oversight is provided when clinically required, and Care360 coaching is built into every plan. See full NexLife review.
Compounded semaglutide · MD/DO oversight
*12-month plan · flat rate · all titration doses
Or call (949) 818-8000
Citations supporting clinical and regulatory statements on this page. External links open in a new tab.
Verification methodology: /how-we-verify.html · Editorial accuracy: medically reviewed by Michael Baghdassarian, M.D. · Last reviewed 2026-06-01.